Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, Floquet A, Vegas H, Bourgeois H, Bengrine Lefevre L, You B, Pommeret F, Lortholary A, Spaeth D, Hardy-Bessard AC, Abdeddaim C, Kaminsky-Forrett MC, Tod M, Kurtz JE, Del Piano F, Meunier J, Raban N, Alexandre J, Mouret-Reynier MA, Ray-Coquard I, Provansal Gross M, Brachet PE. Joly F, et al. Among authors: bengrine lefevre l. Gynecol Oncol. 2022 Sep;166(3):389-396. doi: 10.1016/j.ygyno.2022.06.022. Epub 2022 Jul 26. Gynecol Oncol. 2022. PMID: 35902297 Clinical Trial.
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study.
Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, André T, Louvet C. Afchain P, et al. Among authors: bengrine lefevre l. Bull Cancer. 2009 May;96(5):E18-22. doi: 10.1684/bdc.2009.0871. Epub 2009 May 12. Bull Cancer. 2009. PMID: 19435690 Free article. Clinical Trial.
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M. Mitry E, et al. Among authors: bengrine lefevre l. Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18. Eur J Cancer. 2014. PMID: 25454413 Clinical Trial.
Ovarian cancer in the older patient: where are we now? What to do next?
Rousseau F, Ranchon F, Bardin C, Bakrin N, Lavoué V, Bengrine-Lefevre L, Falandry C. Rousseau F, et al. Among authors: bengrine lefevre l. Ther Adv Med Oncol. 2023 Sep 16;15:17588359231192397. doi: 10.1177/17588359231192397. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37724138 Free PMC article. Review.
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G, Bengrine-Lefevre L, Maindrault-Goebel F, Louvet C, de Gramont A. Bidard FC, et al. Among authors: bengrine lefevre l. Ann Oncol. 2009 Jun;20(6):1042-7. doi: 10.1093/annonc/mdn730. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153116 Free article. Clinical Trial.
[Nasal septum perforation and bevacizumab].
Bengrine-Lefevre L, Afchain P, Chibaudel B, Gervais H, Tournigand C, De Gramont A, Louvet C. Bengrine-Lefevre L, et al. Rev Med Interne. 2011 Apr;32(4):e43-5. doi: 10.1016/j.revmed.2010.04.015. Epub 2010 Jun 17. Rev Med Interne. 2011. PMID: 21470582 French.
Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
Chibaudel B, Tournigand C, Bonnetain F, Maindrault-Goebel F, Lledo G, André T, Larsen AK, Bengrine-Lefevre L, Louvet C, de Gramont A. Chibaudel B, et al. Among authors: bengrine lefevre l. Eur J Cancer. 2013 Dec;49(18):3813-20. doi: 10.1016/j.ejca.2013.07.150. Epub 2013 Sep 3. Eur J Cancer. 2013. PMID: 24011937
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J. Malka D, et al. Among authors: bengrine lefevre l. Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23. Eur J Cancer. 2019. PMID: 31129386 Clinical Trial.
48 results